Central Nervous System News and Research

RSS

Rotating shift workers have lower levels of serotonin

People who work rotating shifts have significantly lower levels of serotonin, a hormone and neurotransmitter in the central nervous system believed to play an important role in the regulation of sleep, according to a study published in the August 1st issue of the journal SLEEP.

3 Aug 2007

Persons with narcolepsy with cataplexy have low levels of protein thought to help regulate sleep

Persons with narcolepsy with cataplexy have low levels of cerebrospinal fluid (CSF) hypocretin-1, a protein thought to help regulate sleep and wakefulness, according to a study published in the August 1st issue of the journal SLEEP.

2 Aug 2007

New risk genes for multiple sclerosis

Two new large-scale genomic studies have honed in on the main genetic pathway associated with multiple sclerosis (MS), while also uncovering new genetic variations in the disease and suggesting a possible link between MS and other autoimmune diseases.

1 Aug 2007

Court rules in favor of Sandoz on Toprol Xl patent

Sandoz was pleased to learn this week that the U.S. Court of Appeals in St. Louis has affirmed a summary judgment by U.S. District Judge Rodney Sippel invalidating patent protection on Toprol XL(R), a beta blocker used to treat angina, heart failure, and high blood pressure.

26 Jul 2007

Itchy and scratchy gene discovered

Itching for a better anti-itch remedy? Your wish may soon be granted now that scientists at Washington University School of Medicine in St. Louis have identified the first gene for the itch sensation in the central nervous system.

26 Jul 2007

Adult survivors of childhood leukemia exercise less putting themselves at risk for obesity

Overcoming pediatric cancer may only mark the beginning of a young survivor's lifelong battle to stay healthy.

24 Jul 2007

Study looks at cancer incidence among recipients of blood from donors

Individuals who receive blood transfusions from donors with undiagnosed cancers are at no higher risk of developing malignant disease than people who receive blood from donors without cancer, according to the results of a retrospective study published in The Lancet last month.

23 Jul 2007

Blood transfusions not likely to spread cancer

23 Jul 2007

New genetic risk factors for restless leg syndrome

In Germany alone 8 million patients are affected by RLS, which makes it one of the most common neurological diseases.

20 Jul 2007

New data about the laws governing embryo development in organisms

Research aimed at understanding the mechanisms underlying embryo development has taken a step forward thanks to collaborative work between biologists specialized in the study of the fruit fly (Drosophila melanogaster) and scientists specialized in the design of mathematical models that simulate the functioning of biological systems.

12 Jul 2007

New genetic function involved in embryo development in organisms

11 Jul 2007

Genetically engineered herpes simplex virus keeps arteries free-flowing

A genetically engineered herpes simplex virus, primarily known for causing cold sores, may help keep arteries "free-flowing" in the weeks following angioplasty or stent placement for patients, according to research published early in the online edition of PNAS (Proceedings of the National Academy of Sciences of the United States of America).

11 Jul 2007

Adiponectin serves as energy-conserving signal to the brain

A fat-derived protein known for its effects on the liver and skeletal muscle might also serve as an energy-conserving signal to the brain during periods of starvation, suggests a new study in the July issue of Cell Metabolism, a publication of Cell Press.

11 Jul 2007

Catalyst Pharmaceutical Partners starts U.S. phase II trial of CPP-109 in patients with cocaine dependence

Catalyst Pharmaceutical Partners, Inc. a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial of CPP-109 in patients with cocaine dependence.

11 Jul 2007